Korea BNC, a bio-biological material specialized company, announced on the 26th through a disclosure of a change of more than 30% in sales or profit structure that it achieved sales of 81 billion KRW, operating profit of 6 billion KRW, and net profit of 26.1 billion KRW based on last year's consolidated financial statements.
Last year, the company significantly expanded market entry of HA fillers and botulinum toxin mainly in the UK, as well as in Europe, Southeast Asia, and Latin America, resulting in a 91.5% increase in sales compared to the previous year. Additionally, steady cost reduction efforts such as selling and administrative expenses led to a turnaround to operating profit, and net profit was attributed to an increase in financial income and the recognition of assets for deficits and tax credits that reduce future corporate tax burdens, resulting in corporate tax gains.
A Korea BNC official stated, "In 2024, sales growth will continue through the global expansion of our flagship filler products and active sales and marketing activities in the domestic market," adding, "For botulinum toxin, we are also aiming for domestic product approval in the first half of the year."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
